Abstract
Researchers have found many similarities between the 2003 severe acute respiratory syndrome (SARS) virus and SARS-CoV-19 through existing data that reveal the SARS's cause. Artificial intelligence (AI) learning models can be created to predict drug structures that can be used to treat COVID-19. Despite the effectively demonstrated repurposed drugs, more repurposed drugs should be recognized. Furthermore, technological advancements have been helpful in the battle against COVID-19. Machine intelligence technology can support this procedure by rapidly determining adequate and effective drugs against COVID-19 and by overcoming any barrier between a large number of repurposed drugs, laboratory/clinical testing, and final drug authorization. This paper reviews the proposed vaccines and medicines for SARS-CoV-2 and the current application of AI in drug repurposing for COVID-19 treatment.
MeSH terms
-
Adenosine Monophosphate / analogs & derivatives
-
Adenosine Monophosphate / therapeutic use
-
Alanine / analogs & derivatives
-
Alanine / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antiviral Agents / therapeutic use
-
Artificial Intelligence*
-
Ascorbic Acid / therapeutic use
-
COVID-19 / prevention & control
-
COVID-19 Drug Treatment*
-
COVID-19 Vaccines / therapeutic use
-
Chloroquine / therapeutic use
-
Deep Learning
-
Drug Combinations
-
Drug Development*
-
Drug Repositioning*
-
Humans
-
Hydroxychloroquine / therapeutic use
-
Immunosuppressive Agents / therapeutic use
-
Lopinavir / therapeutic use
-
Machine Learning
-
Ribavirin / therapeutic use
-
Ritonavir / therapeutic use
-
Vitamins / therapeutic use
Substances
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents
-
COVID-19 Vaccines
-
Drug Combinations
-
Immunosuppressive Agents
-
Vitamins
-
lopinavir-ritonavir drug combination
-
Lopinavir
-
remdesivir
-
Adenosine Monophosphate
-
Ribavirin
-
Hydroxychloroquine
-
Chloroquine
-
tocilizumab
-
Ritonavir
-
Alanine
-
Ascorbic Acid